JP2014505096A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014505096A5 JP2014505096A5 JP2013553014A JP2013553014A JP2014505096A5 JP 2014505096 A5 JP2014505096 A5 JP 2014505096A5 JP 2013553014 A JP2013553014 A JP 2013553014A JP 2013553014 A JP2013553014 A JP 2013553014A JP 2014505096 A5 JP2014505096 A5 JP 2014505096A5
- Authority
- JP
- Japan
- Prior art keywords
- formula
- compound
- administered
- hour
- food intake
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 93
- 239000003814 drug Substances 0.000 claims 23
- 150000003943 catecholamines Chemical class 0.000 claims 21
- 229940079593 drug Drugs 0.000 claims 19
- 230000037406 food intake Effects 0.000 claims 18
- 235000012631 food intake Nutrition 0.000 claims 18
- 150000002148 esters Chemical class 0.000 claims 15
- 150000003839 salts Chemical class 0.000 claims 12
- 229910019142 PO4 Inorganic materials 0.000 claims 9
- 235000021317 phosphate Nutrition 0.000 claims 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 8
- 208000018737 Parkinson disease Diseases 0.000 claims 8
- 125000003118 aryl group Chemical group 0.000 claims 8
- 208000015114 central nervous system disease Diseases 0.000 claims 8
- 208000027232 peripheral nervous system disease Diseases 0.000 claims 8
- 238000011282 treatment Methods 0.000 claims 8
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims 7
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims 7
- 230000002265 prevention Effects 0.000 claims 7
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims 6
- 208000016285 Movement disease Diseases 0.000 claims 6
- 125000003545 alkoxy group Chemical group 0.000 claims 6
- 125000000217 alkyl group Chemical group 0.000 claims 6
- 125000001589 carboacyl group Chemical group 0.000 claims 6
- 125000001072 heteroaryl group Chemical group 0.000 claims 6
- 229960004502 levodopa Drugs 0.000 claims 6
- 229910052760 oxygen Inorganic materials 0.000 claims 6
- 239000010452 phosphate Substances 0.000 claims 6
- 229910052717 sulfur Inorganic materials 0.000 claims 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 5
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 4
- 125000003282 alkyl amino group Chemical group 0.000 claims 4
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 4
- 125000003435 aroyl group Chemical group 0.000 claims 4
- 125000004429 atom Chemical group 0.000 claims 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 4
- 150000004657 carbamic acid derivatives Chemical class 0.000 claims 4
- 125000004663 dialkyl amino group Chemical group 0.000 claims 4
- 229910052736 halogen Inorganic materials 0.000 claims 4
- 150000002367 halogens Chemical class 0.000 claims 4
- 229910052739 hydrogen Inorganic materials 0.000 claims 4
- 239000001257 hydrogen Substances 0.000 claims 4
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- 239000001301 oxygen Substances 0.000 claims 4
- 239000011593 sulfur Substances 0.000 claims 4
- 125000004001 thioalkyl group Chemical group 0.000 claims 4
- 208000012902 Nervous system disease Diseases 0.000 claims 3
- 150000003013 phosphoric acid derivatives Chemical class 0.000 claims 3
- 150000003014 phosphoric acid esters Chemical class 0.000 claims 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 2
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 2
- 206010020772 Hypertension Diseases 0.000 claims 2
- 208000019022 Mood disease Diseases 0.000 claims 2
- 206010030113 Oedema Diseases 0.000 claims 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 2
- 125000001931 aliphatic group Chemical group 0.000 claims 2
- 125000004391 aryl sulfonyl group Chemical group 0.000 claims 2
- 125000004104 aryloxy group Chemical group 0.000 claims 2
- BNQDCRGUHNALGH-UHFFFAOYSA-N benserazide Chemical compound OCC(N)C(=O)NNCC1=CC=C(O)C(O)=C1O BNQDCRGUHNALGH-UHFFFAOYSA-N 0.000 claims 2
- 229960000911 benserazide Drugs 0.000 claims 2
- 230000015572 biosynthetic process Effects 0.000 claims 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 2
- 229910052794 bromium Inorganic materials 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 210000003169 central nervous system Anatomy 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 229910052801 chlorine Inorganic materials 0.000 claims 2
- 239000000460 chlorine Chemical group 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- 125000006310 cycloalkyl amino group Chemical group 0.000 claims 2
- 229910052731 fluorine Inorganic materials 0.000 claims 2
- 239000011737 fluorine Substances 0.000 claims 2
- 125000001153 fluoro group Chemical group F* 0.000 claims 2
- 125000001188 haloalkyl group Chemical group 0.000 claims 2
- 125000005843 halogen group Chemical group 0.000 claims 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 2
- 239000011630 iodine Chemical group 0.000 claims 2
- 229910052740 iodine Chemical group 0.000 claims 2
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims 2
- 125000001624 naphthyl group Chemical group 0.000 claims 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 2
- ASOADIZOVZTJSR-UHFFFAOYSA-N opicapone Chemical compound CC1=C(Cl)C(C)=[N+]([O-])C(Cl)=C1C1=NOC(C=2C=C(C(O)=C(O)C=2)[N+]([O-])=O)=N1 ASOADIZOVZTJSR-UHFFFAOYSA-N 0.000 claims 2
- 210000001428 peripheral nervous system Anatomy 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 230000004962 physiological condition Effects 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 125000005000 thioaryl group Chemical group 0.000 claims 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 2
- 125000000815 N-oxide group Chemical group 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 208000010643 digestive system disease Diseases 0.000 claims 1
- 208000018685 gastrointestinal system disease Diseases 0.000 claims 1
- -1 phosphate ester Chemical class 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 1
- ILVXOBCQQYKLDS-UHFFFAOYSA-N pyridine N-oxide Chemical group [O-][N+]1=CC=CC=C1 ILVXOBCQQYKLDS-UHFFFAOYSA-N 0.000 claims 1
- JOYRKODLDBILNP-UHFFFAOYSA-N urethane group Chemical group NC(=O)OCC JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161441988P | 2011-02-11 | 2011-02-11 | |
| US61/441,988 | 2011-02-11 | ||
| PCT/GB2011/052056 WO2012107708A1 (en) | 2011-02-11 | 2011-10-21 | Administration regime for nitrocatechols |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016220958A Division JP6389498B2 (ja) | 2011-02-11 | 2016-11-11 | ニトロカテコールの投与計画 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014505096A JP2014505096A (ja) | 2014-02-27 |
| JP2014505096A5 true JP2014505096A5 (enExample) | 2014-12-18 |
| JP6148985B2 JP6148985B2 (ja) | 2017-06-14 |
Family
ID=44999798
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013553014A Active JP6148985B2 (ja) | 2011-02-11 | 2011-10-21 | ニトロカテコールの投与計画 |
| JP2016220958A Active JP6389498B2 (ja) | 2011-02-11 | 2016-11-11 | ニトロカテコールの投与計画 |
| JP2018153722A Active JP6568274B2 (ja) | 2011-02-11 | 2018-08-17 | ニトロカテコールの投与計画 |
| JP2019142271A Active JP6843930B2 (ja) | 2011-02-11 | 2019-08-01 | ニトロカテコールの投与計画 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016220958A Active JP6389498B2 (ja) | 2011-02-11 | 2016-11-11 | ニトロカテコールの投与計画 |
| JP2018153722A Active JP6568274B2 (ja) | 2011-02-11 | 2018-08-17 | ニトロカテコールの投与計画 |
| JP2019142271A Active JP6843930B2 (ja) | 2011-02-11 | 2019-08-01 | ニトロカテコールの投与計画 |
Country Status (18)
| Country | Link |
|---|---|
| US (4) | US20140045900A1 (enExample) |
| EP (2) | EP3831382A1 (enExample) |
| JP (4) | JP6148985B2 (enExample) |
| AU (1) | AU2011358842B2 (enExample) |
| BR (2) | BR112013020424A2 (enExample) |
| CA (1) | CA2826080C (enExample) |
| CY (1) | CY1124022T1 (enExample) |
| DK (1) | DK2672973T3 (enExample) |
| ES (1) | ES2855162T3 (enExample) |
| HR (1) | HRP20210474T1 (enExample) |
| HU (1) | HUE054072T2 (enExample) |
| LT (1) | LT2672973T (enExample) |
| PL (1) | PL2672973T3 (enExample) |
| PT (1) | PT2672973T (enExample) |
| RS (1) | RS61643B1 (enExample) |
| RU (1) | RU2639131C2 (enExample) |
| SI (1) | SI2672973T1 (enExample) |
| WO (1) | WO2012107708A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2616377C (en) | 2005-07-26 | 2014-04-01 | David Alexander Learmonth | Nitrocatechol derivatives as comt inhibitors |
| EP1845097A1 (en) | 2006-04-10 | 2007-10-17 | Portela & Ca., S.A. | Oxadiazole derivatives as COMT inhibitors |
| EP2481410B1 (en) | 2007-01-31 | 2016-07-13 | BIAL - Portela & Ca., S.A. | Nitrocatechol derivates as COMT inhibitors administered with a specific dosage regime |
| TW200942531A (en) | 2008-03-17 | 2009-10-16 | Bial Portela & Companhia S A | Crystal forms of a nitrocatechol |
| KR20210009441A (ko) | 2009-04-01 | 2021-01-26 | 바이알 - 포르텔라 앤드 씨에이 에스에이 | 니트로카테콜 유도체를 포함하는 제약 제제 및 그의 제조 방법 |
| US20140045900A1 (en) | 2011-02-11 | 2014-02-13 | Bial-Portela & Ca, S.A. | Administration regime for nitrocatechols |
| PT2791134T (pt) | 2011-12-13 | 2019-12-18 | BIAL PORTELA & Cª S A | Composto químico útil como intermediário para a preparação de um inibidor de catecol-o-metiltransferase |
| JP2018500300A (ja) * | 2014-11-28 | 2018-01-11 | ノヴィファーマ，エス．アー． | パーキンソン病を遅延させるための医薬 |
| WO2017060870A1 (en) | 2015-10-09 | 2017-04-13 | Hermann Russ | Combination of deuterated levodopa with carbidopa and opicapone for the treatment of parkinson`s disease |
| CN105677240B (zh) * | 2015-12-30 | 2019-04-23 | 上海联影医疗科技有限公司 | 数据删除方法及系统 |
| US12097193B2 (en) | 2018-10-05 | 2024-09-24 | Bial—Portela & Ca, S.A. | Methods for the administration of COMT inhibitors |
| CA3112994A1 (en) | 2018-10-05 | 2020-04-09 | Neurocrine Biosciences, Inc. | Methods for the administration of comt inhibitors |
| JP2020023540A (ja) * | 2019-10-11 | 2020-02-13 | ノヴィファーマ，エス．アー． | パーキンソン病を遅延させるための医薬 |
| JP7251026B2 (ja) | 2019-11-14 | 2023-04-04 | 国立大学法人九州大学 | ポリマー化合物およびコーティング組成物 |
| GB202016425D0 (en) * | 2020-10-16 | 2020-12-02 | Bial Portela & Ca Sa | Treatment regimens for parkinson's disease |
| JP2024500754A (ja) * | 2020-12-17 | 2024-01-10 | ビアル－ポルテラ エ コンパニア，ソシエダッド アノニマ | 早期特発性パーキンソン病のための治療レジメン |
Family Cites Families (86)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1532178A (en) | 1921-07-25 | 1925-04-07 | Louis A Godbold | Lubricator |
| FR1260080A (fr) | 1960-03-22 | 1961-05-05 | Materiel De Forage Soc De Fab | Trépan à molettes étanche |
| IL31990A (en) | 1968-04-26 | 1974-05-16 | Chinoin Gyogyszer Es Vegyeszet | Pyridyl 1,2,4-oxadiazole derivatives,process for the preparation thereof and pharmaceutical compositions containing same |
| US4022901A (en) | 1975-03-05 | 1977-05-10 | E. R. Squibb & Sons, Inc. | 3-Pyridinyl-5-isothiocyanophenyl oxadiazoles |
| US4264573A (en) | 1979-05-21 | 1981-04-28 | Rowell Laboratories, Inc. | Pharmaceutical formulation for slow release via controlled surface erosion |
| US4386668A (en) | 1980-09-19 | 1983-06-07 | Hughes Tool Company | Sealed lubricated and air cooled rock bit bearing |
| DK175069B1 (da) | 1986-03-11 | 2004-05-24 | Hoffmann La Roche | Pyrocatecholderivater |
| US5236952A (en) | 1986-03-11 | 1993-08-17 | Hoffmann-La Roche Inc. | Catechol derivatives |
| YU213587A (en) | 1986-11-28 | 1989-06-30 | Orion Yhtymae Oy | Process for obtaining new pharmacologic active cateholic derivatives |
| DE3840954A1 (de) | 1988-12-05 | 1990-06-07 | Shell Int Research | Herstellung von 2-chlornicotinsaeureestern |
| US5206372A (en) | 1990-06-05 | 1993-04-27 | Shell Research Limited | Preparation of 2-chloropyridine derivatives |
| EP0487774B1 (en) | 1990-11-29 | 1994-10-26 | Wei Ming Pharmaceutical Mfg. Co. Ltd. | A direct tabletting auxiliary |
| JPH07502529A (ja) | 1991-12-31 | 1995-03-16 | 藤沢薬品工業株式会社 | アセチルコリンエステラーゼ阻害およびムスカリン様のアゴニスト活性を有するオキサジアゾール誘導体 |
| US6361794B1 (en) | 1996-06-12 | 2002-03-26 | Basf Corporation | Method of making ibuprofen and narcotic analgesic composition |
| DE19628617A1 (de) | 1996-07-16 | 1998-01-22 | Basf Ag | Direkttablettierhilfsmittel |
| US6206110B1 (en) | 1996-09-09 | 2001-03-27 | Smith International, Inc. | Protected lubricant reservoir with pressure control for sealed bearing earth boring drill bit |
| US5788987A (en) * | 1997-01-29 | 1998-08-04 | Poli Industria Chimica Spa | Methods for treating early morning pathologies |
| CZ297284B6 (cs) | 1998-03-27 | 2006-10-11 | Pharmacia & Upjohn Company | Farmaceutiký prostredek pro lécbu syndromu neklidných nohou |
| JP2002526482A (ja) | 1998-09-18 | 2002-08-20 | バーテックス ファーマシューティカルズ インコーポレイテッド | ｐ３８のインヒビター |
| GB2344819A (en) | 1998-12-18 | 2000-06-21 | Portela & Ca Sa | 2-Phenyl-1-(3,4-dihydroxy-5-nitrophenyl)-1-ethanones |
| FI109453B (fi) * | 1999-06-30 | 2002-08-15 | Orion Yhtymae Oyj | Farmaseuttinen koostumus |
| IL131037A (en) | 1999-07-22 | 2004-06-20 | Israel Atomic Energy Comm | Method for making threedimensional photonic band-gap crystals |
| SK2512002A3 (en) | 1999-08-19 | 2002-07-02 | Nps Pharma Inc | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
| US6660753B2 (en) | 1999-08-19 | 2003-12-09 | Nps Pharmaceuticals, Inc. | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
| FI20000635A0 (fi) | 2000-03-17 | 2000-03-17 | Orion Yhtymae Oyj | COMT-inhibiittoreiden käyttö analgeettina |
| SE0001438D0 (sv) | 2000-04-18 | 2000-04-18 | Axon Chemicals Bv | New chemical compounds and their use in therapy |
| DE10029201A1 (de) | 2000-06-19 | 2001-12-20 | Basf Ag | Verfahren zur Herstellung fester oraler Darreichungsformen mit retardierender Wirkstoffreisetzung |
| GB2363792A (en) | 2000-06-21 | 2002-01-09 | Portela & Ca Sa | Nitrocatechols |
| CN1166626C (zh) | 2000-08-30 | 2004-09-15 | 李凌松 | 三或四取代苯基化合物、其制备方法及应用 |
| EP1356046B1 (en) | 2000-11-28 | 2009-10-14 | ZymoGenetics, L.L.C. | Cytokine receptor zcytor19 |
| US20040097555A1 (en) | 2000-12-26 | 2004-05-20 | Shinegori Ohkawa | Concomitant drugs |
| EP1354603A1 (en) | 2000-12-26 | 2003-10-22 | Takeda Chemical Industries, Ltd. | Concomitant drugs |
| DE60234812D1 (de) | 2001-01-29 | 2010-02-04 | Shionogi & Co | Arzneipräparat, das als wirkstoff 5-methyl-1-phenyl-2-(1h)-pyridon enthält |
| KR100838447B1 (ko) | 2001-02-21 | 2008-06-16 | 아스트라제네카 아베 | 헤테로폴리시클릭 화합물 및 대사향성 글루타메이트수용체 길항제로서의 그의 용도 |
| WO2002096867A2 (en) | 2001-05-30 | 2002-12-05 | Lg Biomedical Institute | Inhibitors of protein kinase for the treatment of disease |
| KR20040004705A (ko) | 2001-06-08 | 2004-01-13 | 시토비아 인크. | 카스파제의 활성제 및 아폽토시스의 유도제로서의 치환된3-아릴-5-아릴-[1,2,4]-옥사디아졸과 유사체 및 이의 용도 |
| US6627646B2 (en) | 2001-07-17 | 2003-09-30 | Sepracor Inc. | Norastemizole polymorphs |
| EP1408964B1 (en) | 2001-07-26 | 2007-01-24 | MERCK PATENT GmbH | Use of 2- 5-(4-fluorophenyl)-3-pyridylmethylaminomethyl|-chromane and its physiologically acceptable salts |
| JP4379853B2 (ja) | 2001-10-05 | 2009-12-09 | 惠民製藥股▲分▼有限公司 | 直接錠剤化用調合物および補助剤の調合方法 |
| JP2004115374A (ja) | 2002-09-24 | 2004-04-15 | Masayuki Tanno | 一酸化窒素供与剤としてのピリジン誘導体 |
| US7144876B2 (en) | 2002-12-18 | 2006-12-05 | Cytovia, Inc. | 3,5-Disubstituted-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis and the use thereof |
| JP2006516549A (ja) | 2002-12-23 | 2006-07-06 | メルク フロスト カナダ アンド カンパニー | パーキンソン病の治療用医薬組成物及び治療方法 |
| WO2005006945A2 (en) | 2003-07-03 | 2005-01-27 | The Salk Institute For Biological Studies | Methods for treating neural disorders and compounds useful therefor |
| EP1663211B1 (en) | 2003-08-06 | 2010-01-20 | Vertex Pharmaceuticals Incorporated | Aminotriazole compounds useful as inhibitors of protein kinases |
| DE10338174A1 (de) | 2003-08-20 | 2005-03-24 | Lts Lohmann Therapie-Systeme Ag | Transdermale Arzneimittelzubereitungen mit Wirkstoffkombinationen zur Behandlung der Parkinson-Krankheit |
| WO2005030176A1 (en) | 2003-09-29 | 2005-04-07 | Novo Nordisk Femcare Ag | Improved stability of progestogen formulations |
| US7300406B2 (en) | 2003-09-30 | 2007-11-27 | Carter Vandette B | Medical examination apparatus |
| GB0325956D0 (en) | 2003-11-06 | 2003-12-10 | Addex Pharmaceuticals Sa | Novel compounds |
| DE602005020611D1 (de) | 2004-04-28 | 2010-05-27 | Vertex Pharma | Als inhibitoren von rock und anderen proteinkinasen geeignete zusammensetzungen |
| EP1625849A1 (en) | 2004-08-09 | 2006-02-15 | Liconsa, Liberacion Controlada de Sustancias Activas, S.A. | Pharmaceutical composition comprising drospirenone and ethynylestradiol |
| GB0510143D0 (en) | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds A1 |
| US20060173074A1 (en) | 2004-11-10 | 2006-08-03 | Juha Ellmen | Treatment of restless legs syndrome |
| WO2006061697A1 (en) | 2004-12-06 | 2006-06-15 | Themis Laboratories Private Limited | Sulfonylurea compositions and a process for its preparation |
| JP2008525524A (ja) | 2004-12-28 | 2008-07-17 | アストラゼネカ・アクチエボラーグ | アリールスルホンアミドモジュレーター |
| US20080051441A1 (en) | 2004-12-28 | 2008-02-28 | Astrazeneca Ab | Aryl Sulphonamide Modulators |
| EP1881979B1 (en) | 2005-04-26 | 2010-08-11 | NeuroSearch A/S | Novel oxadiazole derivatives and their medical use |
| US20060257473A1 (en) | 2005-05-11 | 2006-11-16 | Porranee Puranajoti | Extended release tablet |
| GB0510139D0 (en) | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds B1 |
| MX2007015165A (es) | 2005-06-03 | 2008-02-14 | Abbott Lab | Derivados de ciclobutil-amina. |
| JP2007024970A (ja) | 2005-07-12 | 2007-02-01 | Miyakawa:Kk | 液晶表示装置の開口効率を上昇させるための樹脂レンズ製造法及びその製造装置 |
| US20090000437A1 (en) | 2005-07-14 | 2009-01-01 | Provo Craft And Novelty, Inc. | Methods for Cutting |
| CA2616377C (en) * | 2005-07-26 | 2014-04-01 | David Alexander Learmonth | Nitrocatechol derivatives as comt inhibitors |
| FR2889525A1 (fr) | 2005-08-04 | 2007-02-09 | Palumed Sa | Nouveaux derives de polyquinoleines et leur utilisation therapeutique. |
| US20070048384A1 (en) | 2005-08-26 | 2007-03-01 | Joerg Rosenberg | Pharmaceutical compositions |
| WO2007034024A2 (en) | 2005-09-21 | 2007-03-29 | Orion Corporation | Treatment of symptoms of parkinson' s disease |
| WO2007061862A2 (en) | 2005-11-18 | 2007-05-31 | Janssen Pharmaceutica N.V. | 2-keto-oxazoles as modulators of fatty acid amide hydrolase |
| WO2007063946A1 (ja) | 2005-11-30 | 2007-06-07 | Fujifilm Ri Pharma Co., Ltd. | アミロイドの凝集及び／又は沈着に起因する疾患の診断薬及び治療薬 |
| GB0606774D0 (en) | 2006-04-03 | 2006-05-10 | Novartis Ag | Organic compounds |
| EP1845097A1 (en) | 2006-04-10 | 2007-10-17 | Portela & Ca., S.A. | Oxadiazole derivatives as COMT inhibitors |
| PE20080906A1 (es) | 2006-08-17 | 2008-07-05 | Kemia Inc | Derivados heteroarilo como inhibidores de citocina |
| US20080167286A1 (en) | 2006-12-12 | 2008-07-10 | Abbott Laboratories | Pharmaceutical compositions and their methods of use |
| US8486979B2 (en) | 2006-12-12 | 2013-07-16 | Abbvie Inc. | 1,2,4 oxadiazole compounds and methods of use thereof |
| JP2008162955A (ja) | 2006-12-28 | 2008-07-17 | Chugai Pharmaceut Co Ltd | バリン含有高密度顆粒剤 |
| EP2481410B1 (en) * | 2007-01-31 | 2016-07-13 | BIAL - Portela & Ca., S.A. | Nitrocatechol derivates as COMT inhibitors administered with a specific dosage regime |
| AR065802A1 (es) | 2007-03-22 | 2009-07-01 | Schering Corp | Formulaciones de comprimidos que contienen sales de 8- [( 1- ( 3,5- bis- (trifluorometil) fenil) -etoxi ) - metil) -8- fenil -1, 7- diaza- spiro [ 4,5] decan -2- ona y comprimidos elaborados a partir de estas |
| CA2696609C (en) | 2007-08-27 | 2017-09-05 | Helicon Therapeutics, Inc. | Therapeutic isoxazole compounds |
| CN101959504A (zh) | 2008-02-28 | 2011-01-26 | 比艾尔-坡特拉有限公司 | 用于难溶性药物的药物组合物 |
| TW200942531A (en) | 2008-03-17 | 2009-10-16 | Bial Portela & Companhia S A | Crystal forms of a nitrocatechol |
| CN102355900A (zh) * | 2008-07-29 | 2012-02-15 | 比艾尔-坡特拉有限公司 | 硝基儿茶酚的给药方式 |
| KR20210009441A (ko) | 2009-04-01 | 2021-01-26 | 바이알 - 포르텔라 앤드 씨에이 에스에이 | 니트로카테콜 유도체를 포함하는 제약 제제 및 그의 제조 방법 |
| CN105816456A (zh) | 2009-04-01 | 2016-08-03 | 巴尔-波特拉及康邦亚股份有限公司 | 包括硝基儿茶酚衍生物的药物制剂及其制备方法 |
| US8294760B2 (en) * | 2009-04-21 | 2012-10-23 | Samsung Techwin Co., Ltd. | Electronic part recognition apparatus and chip mounter having the same |
| EP2542220B1 (en) * | 2010-03-04 | 2016-11-02 | Orion Corporation | Use of levodopa, carbidopa and entacapone for treating parkinson's disease |
| US20140045900A1 (en) | 2011-02-11 | 2014-02-13 | Bial-Portela & Ca, S.A. | Administration regime for nitrocatechols |
| PT2791134T (pt) | 2011-12-13 | 2019-12-18 | BIAL PORTELA & Cª S A | Composto químico útil como intermediário para a preparação de um inibidor de catecol-o-metiltransferase |
| JP2018500300A (ja) | 2014-11-28 | 2018-01-11 | ノヴィファーマ，エス．アー． | パーキンソン病を遅延させるための医薬 |
-
2011
- 2011-10-12 US US13/583,375 patent/US20140045900A1/en not_active Abandoned
- 2011-10-21 RS RS20210351A patent/RS61643B1/sr unknown
- 2011-10-21 LT LTEP11785058.6T patent/LT2672973T/lt unknown
- 2011-10-21 SI SI201131963T patent/SI2672973T1/sl unknown
- 2011-10-21 AU AU2011358842A patent/AU2011358842B2/en active Active
- 2011-10-21 WO PCT/GB2011/052056 patent/WO2012107708A1/en not_active Ceased
- 2011-10-21 BR BR112013020424-9A patent/BR112013020424A2/pt not_active Application Discontinuation
- 2011-10-21 JP JP2013553014A patent/JP6148985B2/ja active Active
- 2011-10-21 HR HRP20210474TT patent/HRP20210474T1/hr unknown
- 2011-10-21 HU HUE11785058A patent/HUE054072T2/hu unknown
- 2011-10-21 ES ES11785058T patent/ES2855162T3/es active Active
- 2011-10-21 RU RU2013139414A patent/RU2639131C2/ru active
- 2011-10-21 DK DK11785058.6T patent/DK2672973T3/da active
- 2011-10-21 EP EP20217676.4A patent/EP3831382A1/en active Pending
- 2011-10-21 PL PL11785058T patent/PL2672973T3/pl unknown
- 2011-10-21 BR BR112013007380A patent/BR112013007380A2/pt not_active Application Discontinuation
- 2011-10-21 EP EP11785058.6A patent/EP2672973B1/en active Active
- 2011-10-21 CA CA2826080A patent/CA2826080C/en active Active
- 2011-10-21 PT PT117850586T patent/PT2672973T/pt unknown
-
2013
- 2013-08-09 US US13/963,621 patent/US10065944B2/en active Active
-
2016
- 2016-11-11 JP JP2016220958A patent/JP6389498B2/ja active Active
-
2018
- 2018-08-17 JP JP2018153722A patent/JP6568274B2/ja active Active
- 2018-08-28 US US16/114,430 patent/US12129247B2/en active Active
-
2019
- 2019-08-01 JP JP2019142271A patent/JP6843930B2/ja active Active
-
2021
- 2021-03-23 CY CY20211100250T patent/CY1124022T1/el unknown
-
2024
- 2024-10-23 US US18/924,015 patent/US20250276963A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014505096A5 (enExample) | ||
| RU2013139414A (ru) | Режим введения для нитрокатехолов | |
| RU2009132188A (ru) | Режим дозирования ингибиторов комт | |
| JP2012505836A5 (enExample) | ||
| RU2010154173A (ru) | Режим введения нитрокатехолов | |
| CY1109370T1 (el) | Παραγωγα οξαδιαζολονης ως ppar δελτα αγωνιστες | |
| HRP20191795T1 (hr) | Medicinska upotreba spojeva artemizinina i agonista gefirina | |
| JP2009530398A5 (enExample) | ||
| JP2014503593A5 (enExample) | ||
| JP2020512337A5 (enExample) | ||
| JP2013533253A5 (enExample) | ||
| EP4326268A1 (en) | Treatment of cns diseases with sgc stimulators | |
| RU2009145537A (ru) | Терапевтические соединения | |
| JP2013526579A5 (enExample) | ||
| RU2016110546A (ru) | Комбинированная лекарственная терапия | |
| EP2982382A1 (en) | Compounds for preventing ototoxicity | |
| WO2024086182A1 (en) | Treatment of mitochondrial diseases with sgc stimulators | |
| JPWO2022211052A5 (enExample) | ||
| CN105530929B (zh) | 3‑羧基‑n‑乙基‑n,n‑二甲基丙‑1‑铵或其药学上可接受的盐在预防和治疗糖尿病中的用途 | |
| JP2016193903A5 (enExample) |